Correlation of IDH1/2 mutation with clinicopathologic factors and prognosis in anaplastic gliomas: a report of 203 patients from China (Q45819845)

16 December 2017

title

Correlation of IDH1/2 mutation with clinicopathologic factors and prognosis in anaplastic gliomas: a report of 203 patients from China (English)

1 reference

16 December 2017

People's Republic of China

main subject

0 references

author name string

Chuan-Bao Zhang

1

1 reference

16 December 2017

Zhao-Shi Bao

2

1 reference

16 December 2017

Hong-Jun Wang

3

1 reference

16 December 2017

Wei Yan

4

1 reference

16 December 2017

Yan-Wei Liu

5

1 reference

16 December 2017

Ming-Yang Li

6

1 reference

16 December 2017

Wei Zhang

7

1 reference

16 December 2017

Ling Chen

8

1 reference

16 December 2017

Tao Jiang

9

1 reference

16 December 2017

publication date

23 October 2013

1 reference

16 December 2017

Journal of Cancer Research and Clinical Oncology

published in

1 reference

16 December 2017

volume

140

1 reference

16 December 2017

issue

1

1 reference

16 December 2017

page(s)

45-51

1 reference

16 December 2017

Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1519-9

DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1519-9

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1519-9

Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1519-9

The human PICD gene encodes a cytoplasmic and peroxisomal NADP(+)-dependent isocitrate dehydrogenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1519-9

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1519-9

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1519-9

Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1519-9

IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1519-9

Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1519-9

Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1519-9

The 2007 WHO classification of tumours of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1519-9

Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1519-9

IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1519-9

An integrated genomic analysis of human glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1519-9

Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1519-9

IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1519-9

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1519-9

IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1519-9

Understanding high grade glioma: molecular mechanism, therapy and comprehensive management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1519-9

IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1519-9

IDH1 and IDH2 mutations in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1519-9

Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1519-9

Management and survival rates in patients with glioma in China (2004-2010): a retrospective study from a single-institution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1519-9

Antiangiogenic therapy with bevacizumab in recurrent malignant gliomas: analysis of the response and core pathway aberrations.

21 January 2018

1 reference

12 December 2020

IDH1 mutation of gliomas with long-term survival analysis

1 reference

12 December 2020

O(6)-methylguanine-DNA methyltransferase in glioma therapy: promise and problems

1 reference

12 December 2020

Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT.

1 reference

12 December 2020

10.1007/S00432-013-1519-9

Identifiers

DOI

1 reference

16 December 2017

Dimensions Publication ID

1025734268

0 references

1 reference

16 December 2017